PT - JOURNAL ARTICLE AU - Parcesepe, Angela M AU - Robertson, McKaylee AU - Berry, Amanda AU - Maroko, Andrew AU - Zimba, Rebecca AU - Grov, Christian AU - Westmoreland, Drew AU - Kulkarni, Sarah AU - Rane, Madhura AU - Salgado-You, William AU - Mirzayi, Chloe AU - Waldron, Levi AU - Nash, Denis TI - The relationship between anxiety, health, and potential stressors among adults in the United States during the COVID-19 pandemic AID - 10.1101/2020.10.30.20221440 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.30.20221440 4099 - http://medrxiv.org/content/early/2020/11/04/2020.10.30.20221440.short 4100 - http://medrxiv.org/content/early/2020/11/04/2020.10.30.20221440.full AB - Objective To estimate the prevalence of anxiety symptoms and the association between moderate or severe anxiety symptoms and health and potential stressors among adults in the U.S. during the COVID-19 pandemicMethods This analysis includes data from 5,250 adults in the Communities, Households and SARS/CoV-2 Epidemiology (CHASING) COVID Cohort Study surveyed in April 2020. Poisson models were used to estimate the association between moderate or severe anxiety symptoms and health and potential stressors among U.S. adults during the COVID-19 pandemic.Results Greater than one-third (35%) of participants reported moderate or severe anxiety symptoms. Having lost income due to COVID-19 (adjusted prevalence ratio [aPR] 1.27 (95% CI 1.16, 1.30), having recent COVID-like symptoms (aPR 1.17 (95% CI 1.05, 1,31), and having been previously diagnosed with depression (aPR 1.49, (95% CI 1.35, 1.64) were positively associated with anxiety symptoms.Conclusions Anxiety symptoms were common among adults in the U.S. during the COVID-19 pandemic. Strategies to screen and treat individuals at increased risk of anxiety, such as individuals experiencing financial hardship and individuals with prior diagnoses of depression, should be developed and implemented.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for this project is provided by the CUNY Institute for Implementation Science in Population Health (cunyisph.org), the COVID-19 Grant Program of the CUNY Graduate School of Public Health and Health Policy, and the National Institute Of Allergy and Infectious Diseases of the National Institutes of Health under Award Number UH3AI133675 and NICHD grant P2C HD050924 (Carolina Population Center).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board at the City University of New York Graduate School of Public Health.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available upon reasonable request from CUNY ISPH. The data are not yet publicly available, but we are preparing to post a deidentified, HIPAA compliant, public use version of our baseline and follow-up data on GitHub.